ABBV AbbVie Inc.

AbbVie has delivered a powerful 187.5% total return over the past 5 years, so the current US$261.59 share price naturally raises a question for investors who care about cash generation. With fresh drug approvals, pipeline updates and new partnerships in the headlines, the key issue now is whether AbbVie’s cash flows are strong enough and durable enough to underpin where the stock trades today. That 187.5% 5 year return puts real pressure on the valuation question, because a move of that size...

Eli Lilly (LLY) management said on its second-quarter 2026 call that the price of Zepbound, its obesity drug, will go down. The company's sales growth rests on two drugs whose prices are falling - Zepbound and Mounjaro. That makes it difficult to call the stock's coming twelve months. So how do you really understand the risk you are taking with Eli Lilly stock? Well, you can look at the options market.

An income portfolio built inside one sector carries one set of risks. This basket spreads five dividend payers across four sectors: consumer staples with Coca-Cola (NYSE:KO) and PepsiCo (NASDAQ:PEP), financials with JPMorgan Chase (NYSE:JPM), real estate with Realty Income (NYSE:O) and healthcare with AbbVie (NYSE:ABBV). The sections run by sector because the goal is diversity […]

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

With the 10-year Treasury now paying more than most income stocks, five dividend names face a simple question: does real cash actually back the payout, or just the yield number on the screen?

AbbVie's stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive pressures remain.

Johnson & Johnson (JNJ) stock returned around 52% in the twelve months, against 17% for the S&P 500. A $10,000 holding became about $15,220. Over that period, J&J’s revenue growth accelerated even as the company navigated the anticipated loss of exclusivity and biosimilar erosion for STELARA. If that shift showed up in J&J's calls and filings first, a reader could have spotted it early. So was J&J's run in plain sight before it began.

AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.

Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.

AbbVie (NYSE: ABBV) reported Phase 2 APEX Part B data for zumilokibart in moderate to severe atopic dermatitis at the EADV Congress. The company selected a mid dose of zumilokibart for Phase 3 development after the study showed significant clinical improvements in patients. AbbVie joined the Antibody Developability Consortium as a founding member and started a new AI driven R&D collaboration with Valkai. The zumilokibart Phase 2 results and AbbVie’s new AI alliances matter, but investors...

Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

Bank of America just raised price targets on two pharma giants facing patent cliffs, but its conviction level differs sharply between them, and the valuation gap may explain which one belongs in a long-term portfolio right now.

AbbVie (ABBV) closed the most recent trading day at $263.29, moving 1.12% from the previous trading session.

Several members of the elite Dividend Kings club, including JNJ, KO, and ABBV, are known for dividend reliability, each with a long, consistent history of increasing payouts. The trio boasts a strong defensive nature given consumers' needs for their products no matter the backdrop.

You may own Eli Lilly (LLY), a drugmaker worth about $1.05 trillion, beside funds that already track the S&P 500. A single stock can become a big part of your money, so its daily moves matter for all of it. Is Eli Lilly stock a good fit for the risk you already carry.

The liquidation auctioneer Liquidity Services is closing in on a buy point. The stock is up roughly 45% this year.

Eli Lilly (LLY) raised its revenue forecast for 2026 on August 5, when it reported second-quarter results. Since the close before that release, Eli Lilly stock has gained 6.3%, while the S&P 500 fell 0.7%. The raise was modest and came with a lower earnings forecast, which is why the price chart is worth a look. So does Eli Lilly's price chart agree with management.

The once-daily treatment reaches the U.S. market in October after improving motor-control measures across three Phase 3 studies.

ABBV wins FDA approval for Juvmo, expanding its Parkinson's portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.

GOOGL, MA and ABBV headline today's research, with AI-led growth, electronic payments and strong drug portfolios shaping their outlooks.

AbbVie recently received U.S. FDA approval for JUVMO (tavapadon) tablets, the first and only selective D1/D5 receptor agonist for adults with Parkinson’s disease, offering a new way to manage motor symptoms alongside existing levodopa-based regimens. This approval adds a differentiated mechanism within AbbVie’s neuroscience portfolio, potentially helping clinicians manage levodopa dose escalation and treatment-related complications in Parkinson’s care. We’ll now examine how JUVMO’s...

AbbVie (ABBV) just secured U.S. FDA approval for JUVMO, a Parkinson's disease pill that targets D1/D5 receptors. This gives the neuroscience portfolio a new pillar supported by late stage efficacy and safety data. AbbVie shares have been trending higher, with a 30 day share price return of 4.23% and a year to date gain of 16.12%. Total shareholder return sits at 23.02% over one year and almost doubles over three years, suggesting momentum has been building as new approvals like JUVMO, RINVOQ...

Key Stats for AbbVie StockCurrent Price: $264. 34Target Price (Mid): ~$363Street Target: ~$279Potential Total Return: ~37%Annualized IRR: ~8% / yearWhat Happened?The FDA approved Juvmo (tavapadon), a once-daily Parkinson’s pill from AbbVie (ABBV), on Friday, September 25, according to Reuters.

The FDA approved Juvmo as the first and only selective D1/D5 receptor agonist for adults with Parkinson's disease, with a U.S. launch planned for October.

AbbVie Inc (NYSE:ABBV) received approval from the U. S.

BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.

AbbVie Inc. (NYSE:ABBV) and Iambic announced a multi-year collaboration to use Iambic’s AI platform to accelerate small-molecule drug discovery across immunology, neuroscience, and oncology. The partnership will use Iambic’s Enchant v3 model, which is trained on more than 6,000 molecular properties and is designed to evaluate multiple drug characteristics simultaneously. The companies will pursue candidates […]

Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.

Chasing the highest dividend yield is exactly how investors end up owning something that quietly eats their principal alive. A six-holding portfolio shows how a much lower yield can generate far more income a decade from now than a double-digit payout ever could.

AbbVie (NYSE:ABBV) acquired a stake in ADARx Pharmaceuticals during its IPO, gaining exposure to RNA interference drug candidates. The investment in ADARx ties AbbVie to RNA-based therapies being developed for certain rare disease indications. Health Canada granted marketing authorization for AbbVie's EPKINLY for adults with relapsed or refractory follicular lymphoma. AbbVie's move into ADARx's IPO and the new EPKINLY approval both need weighing against the rest of our ABBV thesis. We have...

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

At about $1,182 a share, Eli Lilly (LLY) stock trades at about 33.1 times trailing earnings. Those are adjusted earnings: normalized net income with stock-based compensation added back, a basis built to sit close to the one analysts use in their forecasts. That looks expensive. Whether it is depends on two obesity drugs, on margins and on how much Lilly spends buying new medicines.

The pharmaceutical giant sent shareholders a torrent of cash, yet the stock itself went backward. Here is the accounting of what owners actually received.

AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to rethink their income strategy completely.

The San Diego RNA drug developer sold 26.3 million shares at $17 apiece, with AbbVie investing up to $100 million in a concurrent private placement

Peptides are everywhere lately. Influencers inject them for muscle and recovery, and the Food and Drug Administration could soon allow these products to be sold by compounding pharmacies. While the marketing of these injections to biohackers and wellness consumers will keep generating debate, the peptide boom that matters to biotech investors belongs to a company most TikTokers have never heard of.

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

Iambic widens the discovery search, but AbbVie disclosed no targets, payment amounts or development timetable.

Eli Lilly (LLY) grew revenue 49.6% over the last twelve months, the fastest of the six companies in its peer group. It also runs the group's widest operating margin, at 49.7%. Yet its 53.4% stock return ranks only third, behind Merck and Johnson & Johnson, which both grew far more slowly. The open question is how long Mounjaro and Zepbound can carry a lead the stock has not matched.

Oruka Therapeutics' (ORKA) lead program of long-acting IL-23 in moderate-to-severe psoriasis maintai

AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.

ABBV is expanding its oncology pipeline with newer therapies and diverse approaches to offset Imbruvica's decline.

It would be hard for investors to replicate the company's return over the past decade.

AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S. IPO on September 21 after raising money from NVIDIA Corporation (NASDAQ:NVDA) and Qatar Investment Authority, and the same day announced a multi-year research collaboration with AbbVie Inc. (NYSE:ABBV). Iambic will use its AI platform to […]

AbbVie's management has changed what it puts first on its earnings calls. One growth figure used to open the script. Management last mentioned that figure in the fiscal fourth quarter 2025 call. AbbVie (ABBV) never said it would stop reporting it. So which figure was it, and why did it matter.